LOXL2 Protein, Human (HEK293, His)

LOXL2 protein mediates post-translational oxidative deamination of lysine residues, leading to the formation of allysine. It specifically deaminates H3K4me3, inhibits TFIID-dependent transcription, represses E-cadherin, activates the IRE1-XBP1 pathway, and promotes cross-linking of extracellular matrix proteins. LOXL2 is involved in EMT, tumor progression, angiogenesis regulation, and chondrocyte differentiation. LOXL2 Protein, Human (HEK293, His) is the recombinant human-derived LOXL2 protein, expressed by HEK293 , with C-His labeled tag.

The LOXL2 protein functions as a mediator in the post-translational oxidative deamination of lysine residues on target proteins, leading to the formation of deaminated lysine (allysine). Acting as a transcription corepressor, LOXL2 specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Notably, LOXL2 does not exhibit activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2). Additionally, LOXL2 mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, inducing the release of TAF10 from promoters and leading to the inhibition of TFIID-dependent transcription. This repression results in the downregulation of genes essential for embryonic stem cell pluripotency, including POU5F1/OCT4, NANOG, KLF4, and SOX2. LOXL2 is involved in epithelial to mesenchymal transition (EMT), participating in the repression of E-cadherin (CDH1) through the deamination of histone H3. It interacts with the endoplasmic reticulum protein HSPA5, activating the IRE1-XBP1 pathway of the unfolded protein response, and is implicated in E-cadherin repression following hypoxia, potentially contributing to tumor progression. Furthermore, when secreted into the extracellular matrix, LOXL2 promotes the cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. It also acts as a regulator of sprouting angiogenesis and chondrocyte differentiation.

Measured by its ability to produce hydrogen peroxide during the oxidation of benzylamine. The specific activity is 7.47 pmol/min/μg.

Human

HEK293

C-His

Q9Y4K0 (M26-Q774)

4017  [NCBI]

MERPLCSHLCSCLAMLALLSPLSLAQYDSWPHYPEYFQQPAPEYHQPQAPANVAKIQLRLAGQKRKHSEGRVEVYYDGQWGTVCDDDFSIHAAHVVCRELGYVEAKSWTASSSYGKGEGPIWLDNLHCTGNEATLAACTSNGWGVTDCKHTEDVGVVCSDKRIPGFKFDNSLINQIENLNIQVEDIRIRAILSTYRKRTPVMEGYVEVKEGKTWKQICDKHWTAKNSRVVCGMFGFPGERTYNTKVYKMFASRRKQRYWPFSMDCTGTEAHISSCKLGPQVSLDPMKNVTCENGLPAVVSCVPGQVFSPDGPSRFRKAYKPEQPLVRLRGGAYIGEGRVEVLKNGEWGTVCDDKWDLVSASVVCRELGFGSAKEAVTGSRLGQGIGPIHLNEIQCTGNEKSIIDCKFNAESQGCNHEEDAGVRCNTPAMGLQKKLRLNGGRNPYEGRVEVLVERNGSLVWGMVCGQNWGIVEAMVVCRQLGLGFASNAFQETWYWHGDVNSNKVVMSGVKCSGTELSLAHCRHDGEDVACPQGGVQYGAGVACSETAPDLVLNAEMVQQTTYLEDRPMFMLQCAMEENCLSASAAQTDPTTGYRRLLRFSSQIHNNGQSDFRPKNGRHAWIWHDCHRHYHSMEVFTHYDLLNLNGTKVAEGHKASFCLEDTECEGDIQKNYECANFGDQGITMGCWDMYRHDIDCQWVDITDVPPGDYLFQVVINPNFEVAESDYSNNIMKCRSRYDGHRIWMYNCHIGGSFSEETEKKFEHFSGLLNNQLSPQ

Approximately 110 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.